I Mab Stock Investor Sentiment

IMAB Stock  USD 0.93  0.02  2.11%   
About 62% of I Mab's investor base is looking to short. The analysis of the overall investor sentiment regarding I Mab suggests that many traders are alarmed. The current market sentiment, together with I Mab's historical and current headlines, can help investors time the market. In addition, many technical investors use I Mab stock news signals to limit their universe of possible portfolio assets.
  

I Mab Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards I Mab can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at news.google.com         
London close Stocks mixed as investors hope for Fed pause ... - London South East
Google News at Macroaxis
over a year ago at news.google.com         
SinoMab Submits another IND Application for SM17 for the ... - JCN Newswire
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Retail investors account for 40 percent of I-Mabs ownership, while institutions account for 17
Yahoo News
over a year ago at news.google.com         
OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi at the ASCO 2023 Annual Meeting - Marke...
Google News at Macroaxis
over a year ago at news.google.com         
Asco 2023 Dizal heralds a super-Tagrisso - Evaluate Pharma
Google News at Macroaxis
over a year ago at news.google.com         
Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting - Marketscreene...
Google News at Macroaxis
over a year ago at news.google.com         
Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clin...
Google News at Macroaxis
over a year ago at finance.yahoo.com         
I-Mab Reveals Promising Results in Phase 1b2 Study for Advanced Non-Small Cell Lung Cancer Treatment
Yahoo News
over a year ago at investing.com         
I-Mab Biopharma Announces Encouraging Phase 1b2 Study Results of Patients with Advanced NSCLC Receiv...
Investing News at Macroaxis
over a year ago at finance.yahoo.com         
I-Mab Announces Encouraging Phase 1b2 Study Results of Patients with Advanced NSCLC Receiving Uliled...
Yahoo News
over a year ago at news.google.com         
The Returns At Mitchells Butlers Arent Growing - Simply Wall St
Google News at Macroaxis
over a year ago at news.google.com         
Elevation Oncology Reports First Quarter 2023 Financial Results ... - PR Newswire
Google News at Macroaxis
over a year ago at news.google.com         
London midday Stocks trade mixed as investors eye US debt ceiling ... - London South East
Google News at Macroaxis
over a year ago at news.google.com         
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
TRACON Pharmaceuticals Reports First Quarter 2023 Financial ... - GlobeNewswire
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about I Mab that are available to investors today. That information is available publicly through IMAB media outlets and privately through word of mouth or via IMAB internal channels. However, regardless of the origin, that massive amount of IMAB data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of I Mab news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of I Mab relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to I Mab's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive I Mab alpha.

I Mab Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
09/10/2024
2
I-Mabs Buy Rating Reiterated at HC Wainwright
09/20/2024
3
IMab Moves to Buy Rationale Behind the Upgrade
10/09/2024
4
I-Mab to Participate at the Truist Securities BioPharma Symposium - Morningstar
10/28/2024
5
I-Mab names Sean Fu as CEO
11/06/2024
6
I-Mab Reports Third Quarter 2024 Results
11/14/2024

Complementary Tools for IMAB Stock analysis

When running I Mab's price analysis, check to measure I Mab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy I Mab is operating at the current time. Most of I Mab's value examination focuses on studying past and present price action to predict the probability of I Mab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move I Mab's price. Additionally, you may evaluate how the addition of I Mab to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Valuation
Check real value of public entities based on technical and fundamental data
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins